ROIV insider filings

Roivant Sciences Ltd. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen ROIV transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 41 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Gold Daniel Allen — Director3—7 legs · 1,381,762 sh · $53,536,7386
MANCHESTER KEITH S — Director2—7 legs · 1,381,762 sh · $53,536,7385
QVT Financial LP1—7 legs · 1,381,762 sh · $53,536,7383
Venker Eric — President & Immunovant CEO7—9 legs · 1,187,943 sh · $43,697,1345
Pulik Richard — CFO3—4 legs · 300,000 sh · $12,473,2726
Fitzgerald Meghan — Director4—3 legs · 25,112 sh · $1,001,1525
Epperly Melissa B, — Director5—4 legs · 22,688 sh · $837,0917
Gline Matthew — CEO, Director3——9
Sukhatme Mayukh — President & CIO, Director3——9
Torti Frank — President and Vant Chair2——8

+4 more insiders in the window, not shown — every filing appears in the table below.

Recent insider filings — Roivant Sciences Ltd.

FiledFormInsiderReported transactionsSource
2026-11-193Hammerbacher Jeffrey Evan — DirectorHoldings only — no transactions reportedEDGAR
2026-11-184MANCHESTER KEITH S — DirectorSale (S): 79,461 @ $39.17 · Sale (S): 550,280 @ $39.17 · Sale (S): 18,927 @ $38.99 · Sale (S): 131,073 @ $38.99 · Other (J): 2,635,169 @ $0 · Other (J): 15,969 @ $0 · +4 moreEDGAR
2026-11-184Gold Daniel Allen — DirectorSale (S): 79,461 @ $39.17 · Sale (S): 550,280 @ $39.17 · Sale (S): 18,927 @ $38.99 · Sale (S): 131,073 @ $38.99 · Other (J): 2,635,169 @ $0 · Other (J): 15,969 @ $0 · +4 moreEDGAR
2026-11-184QVT Financial LPSale (S): 79,461 @ $39.17 · Sale (S): 550,280 @ $39.17 · Sale (S): 18,927 @ $38.99 · Sale (S): 131,073 @ $38.99 · Other (J): 2,635,169 @ $0 · Other (J): 15,969 @ $0 · +4 moreEDGAR
2026-11-124Torti Frank — President and Vant ChairOther (J): 173,683 @ $40.43 · Other (J): 218,369 @ $41.13 · Other (J): 240,755 @ $41.63 · Other (J): 151,293 @ $42.01 · Other (J): 329,550 @ $40.36 · Other (J): 62,493 @ $41.13 · +1 moreEDGAR
2026-11-124Gline Matthew — CEO, DirectorOther (J): 25,841 @ $40.43 · Other (J): 32,490 @ $41.13 · Other (J): 30,083 @ $41.63 · Other (J): 18,905 @ $42.01 · Other (J): 41,179 @ $40.36 · Other (J): 7,809 @ $41.13 · +1 moreEDGAR
2026-11-124Sukhatme Mayukh — President & CIO, DirectorOther (J): 26,152 @ $40.43 · Other (J): 32,882 @ $41.13 · Other (J): 32,672 @ $41.63 · Other (J): 20,533 @ $42.01 · Other (J): 44,723 @ $40.36 · Other (J): 8,482 @ $41.13 · +1 moreEDGAR
2026-11-124Venker Eric — President & Immunovant CEOSale (S): 158,194 @ $40.44 · Sale (S): 29,749 @ $41EDGAR
2026-11-124Pulik Richard — CFOOption exercise (M): 125,000 @ $3.85 · Sale (S): 125,000 @ $41.20 · Option exercise (M): 127,365 @ $3.85 · Sale (S): 45,195 @ $41.47 · Sale (S): 82,170 @ $42.03 · Sale (S): 47,635 @ $41.89 · +2 moreEDGAR
2026-11-054Venker Eric — President & Immunovant CEOSale (S): 200,000 @ $36.31EDGAR
2026-10-304Venker Eric — President & Immunovant CEOSale (S): 200,000 @ $36.59EDGAR
2026-10-274MOMTAZEE JAMES C — DirectorGrant/award (A): 383 @ $0 · Tax withholding (F): 77 @ $36.49EDGAR
2026-10-274Epperly Melissa B, — DirectorGrant/award (A): 513 @ $0 · Tax withholding (F): 116 @ $36.49EDGAR
2026-10-274Oren Ilan — DirectorGrant/award (A): 810 @ $0EDGAR
2026-10-224Venker Eric — President & Immunovant CEOSale (S): 185,856 @ $35.09 · Sale (S): 14,144 @ $35.42EDGAR
2026-10-204Gline Matthew — CEO, DirectorTax withholding (F): 34,638 @ $33.53EDGAR
2026-10-204Sukhatme Mayukh — President & CIO, DirectorTax withholding (F): 19,976 @ $33.53EDGAR
2026-10-054Epperly Melissa B, — DirectorOption exercise (M): 17,750 @ $4.46 · Sale (S): 16,850 @ $36.08 · Sale (S): 900 @ $36.57 · Option exercise (M): 17,750 (derivative) @ $0EDGAR
2026-10-024Torti Frank — President and Vant ChairTax withholding (F): 40,309 @ $36.57EDGAR
2026-10-024Gline Matthew — CEO, DirectorTax withholding (F): 76,171 @ $36.57EDGAR
2026-10-024Sukhatme Mayukh — President & CIO, DirectorTax withholding (F): 46,879 @ $36.57EDGAR
2026-10-024Venker Eric — President & Immunovant CEOOption exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $36.62 · Option exercise (M): 200,000 (derivative) @ $0EDGAR
2026-09-224Humes Jennifer — Chief Accounting OfficerTax withholding (F): 3,880 @ $39.77EDGAR
2026-09-224Pulik Richard — CFOTax withholding (F): 2,129 @ $39.77EDGAR
2026-09-184MANCHESTER KEITH S — DirectorGrant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0EDGAR
2026-09-184Gold Daniel Allen — DirectorGrant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0EDGAR
2026-09-184Oren Ilan — DirectorGrant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0EDGAR
2026-09-184MOMTAZEE JAMES C — DirectorGrant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0EDGAR
2026-09-184Epperly Melissa B, — DirectorGrant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0EDGAR
2026-09-184Fitzgerald Meghan — DirectorGrant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0EDGAR
2026-09-174Epperly Melissa B, — DirectorSale (S): 4,338 @ $39.65 · Sale (S): 600 @ $40.38EDGAR
2026-09-174Fitzgerald Meghan — DirectorSale (S): 4,712 @ $39.68 · Sale (S): 400 @ $40.45EDGAR
2026-09-144Gold Daniel Allen — DirectorTax withholding (F): 5,133 @ $40.94EDGAR
2026-09-144Oren Ilan — DirectorTax withholding (F): 2,378 @ $40.94EDGAR
2026-09-144Epperly Melissa B, — DirectorTax withholding (F): 2,179 @ $40.94EDGAR
2026-09-144Fitzgerald Meghan — DirectorTax withholding (F): 1,743 @ $40.94EDGAR
2026-09-144MOMTAZEE JAMES C — DirectorTax withholding (F): 2,905 @ $40.94EDGAR
2026-09-104Fitzgerald Meghan — DirectorOption exercise (M): 20,000 @ $8.80 · Sale (S): 20,000 @ $39.90 · Option exercise (M): 20,000 (derivative) @ $0EDGAR
2026-09-014Venker Eric — President & Immunovant CEOOption exercise (M): 200,000 @ $3.85 · Sale (S): 166,182 @ $35.63 · Sale (S): 33,818 @ $36.44 · Option exercise (M): 200,000 (derivative) @ $0EDGAR
2026-08-244Pulik Richard — CFOTax withholding (F): 5,749 @ $36.84EDGAR
2026-08-244Venker Eric — President & Immunovant CEOTax withholding (F): 13,909 @ $36.84EDGAR
2026-08-214Sukhatme Mayukh — President & CIO, DirectorOption exercise (M): 172,899 @ $3.85 · Sale (S): 172,899 @ $37.17 · Option exercise (M): 17,519 @ $3.85 · Sale (S): 17,519 @ $37.30 · Option exercise (M): 144,756 @ $3.85 · Sale (S): 144,756 @ $36.48 · +3 moreEDGAR
2026-08-184Sukhatme Mayukh — President & CIO, DirectorOption exercise (M): 243,177 @ $3.85 · Sale (S): 243,177 @ $36.23 · Option exercise (M): 284,707 @ $3.85 · Sale (S): 284,707 @ $36.25 · Option exercise (M): 105,141 @ $3.85 · Sale (S): 105,141 @ $36.59 · +5 moreEDGAR
2026-07-294Venker Eric — President & Immunovant CEOOption exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $34.95 · Option exercise (M): 200,000 (derivative) @ $0EDGAR
2026-07-214Epperly Melissa B, — DirectorGrant/award (A): 543 @ $0EDGAR
2026-07-214Oren Ilan — DirectorGrant/award (A): 775 @ $0EDGAR
2026-07-214MOMTAZEE JAMES C — DirectorGrant/award (A): 405 @ $0EDGAR
2026-07-024Torti Frank — President and Vant ChairTax withholding (F): 40,310 @ $35.39EDGAR
2026-07-024Sukhatme Mayukh — President & CIO, DirectorTax withholding (F): 46,878 @ $35.39EDGAR
2026-07-024Fitzgerald Meghan — DirectorOption exercise (M): 10,000 @ $8.80 · Sale (S): 10,000 @ $34.90 · Option exercise (M): 10,000 (derivative) @ $0EDGAR

Recent 8-K events — Roivant Sciences Ltd.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-098-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-218-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-188-K5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-088-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-288-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-278-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-208-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-028-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-238-K/A1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ROIV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs